Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DUPILUMAB Cause Accidental exposure to product? 10,747 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 10,747 reports of Accidental exposure to product have been filed in association with DUPILUMAB (Dupixent). This represents 2.8% of all adverse event reports for DUPILUMAB.

10,747
Reports of Accidental exposure to product with DUPILUMAB
2.8%
of all DUPILUMAB reports
10
Deaths
169
Hospitalizations

How Dangerous Is Accidental exposure to product From DUPILUMAB?

Of the 10,747 reports, 10 (0.1%) resulted in death, 169 (1.6%) required hospitalization, and 1 (0.0%) were considered life-threatening.

Is Accidental exposure to product Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DUPILUMAB. However, 10,747 reports have been filed with the FAERS database.

What Other Side Effects Does DUPILUMAB Cause?

Pruritus (44,279) Dermatitis atopic (33,670) Product use in unapproved indication (33,452) Rash (30,895) Injection site pain (27,799) Drug ineffective (23,712) Dry skin (20,239) Eczema (20,020) Product dose omission issue (18,189) Condition aggravated (16,459)

What Other Drugs Cause Accidental exposure to product?

EVOLOCUMAB (16,160) ERENUMAB-AOOE (9,923) ETANERCEPT (6,065) PEGFILGRASTIM (4,967) GUSELKUMAB (2,941) SECUKINUMAB (2,397) GOLIMUMAB (1,578) USTEKINUMAB (1,352) FREMANEZUMAB-VFRM (1,346) DENOSUMAB (1,330)

Which DUPILUMAB Alternatives Have Lower Accidental exposure to product Risk?

DUPILUMAB vs DURAGESIC DUPILUMAB vs DUROGESIC DUPILUMAB vs DUROTEP MT DUPILUMAB vs DURVALUMAB DUPILUMAB vs DUTASTERIDE

Related Pages

DUPILUMAB Full Profile All Accidental exposure to product Reports All Drugs Causing Accidental exposure to product DUPILUMAB Demographics